[en] Synovial fluid (SF) levels of soluble CD23 (sCD23) were determined in 96 patients presenting with an inflammatory knee effusion (73 with RA and 23 with reactive arthritis (ReA) serving as a control inflammatory non-erosive group) and were correlated with the degree of joint destruction, with local immune parameters (IL-1beta, IL-3, IL-4, IL-6, IL-8, IL-10, IL-12 and sCD25) and with serum markers of inflammation, C-reactive protein and erythrocyte sedimentation rate. RA patients, classified as erosive or not according to Larsen's grade, were separated as follows: (i) 13 patients with non-erosive RA; (ii) 16 RA patients with erosions in hands but not in knees, matched for disease duration with the first group; (iii) 44 RA patients with hand and knee erosions, matched with the second group for rheumatoid factor positivity but of longer disease duration. SF sCD23 levels were significantly increased in both erosive RA groups compared with non-erosive diseases, whether RA or ReA (P < 0.05), whose SF levels were not different. SF IL-10 showed a similar profile to that of SF sCD23 and was the only other parameter characteristic of erosive RA, but no direct correlation was found between the two. SF sCD23 was significantly correlated with IL-12 (r = 0.65, P = 0.0001) and sCD25 (r = 0.39, P = 0.0019) exclusively in the two erosive RA populations. In conclusion, these data showing that increased levels of sCD23 are not only found in the SF of erosive joints but also in knee SF of patients with erosive RA but without knee x-ray-diagnosed erosions suggest that this parameter might be of predictive value for joint destruction. Longitudinal studies are however needed to confirm its potential clinical interest.
Disciplines :
Hematology
Author, co-author :
Ribbens, Clio ; Centre Hospitalier Universitaire de Liège - CHU > Rhumatologie
Bonnet, V.
Kaiser, Marie-Joëlle ; Centre Hospitalier Universitaire de Liège - CHU > Rhumatologie
Andre, Béatrice ; Centre Hospitalier Universitaire de Liège - CHU > Rhumatologie - Néphrologie
Kaye, O.
Franchimont, N.
De Groote, D.
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Malaise, Michel ; Centre Hospitalier Universitaire de Liège - CHU > Rhumatologie
Language :
English
Title :
Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA).
Delespesse G, Suter U, Mossalayi D et al. Expression, structure and function of the CD23 antigen. Adv Immunol 1991; 49:149-91.
Delespesse G, Sarfati M, Wu CY, Fournier S, Letellier M. The low-affinity receptor for IgE. Immunol Rev 1992; 125:77-97.
Sarfati M, Fournier S, Wu CY, Delespesse G. Expression, regulation and function of human Fc epsilon RII (CD23) antigen. Immunol Res1992; 11:260-72.
Liu YJ, Cairns JA, Holder MJ, Abbot SD, Jansen KU, Bonnefoy JY, Gordon J, MacLennan ICM. Recombinant 25-kDa CD23 and interleukin 1α promote the survival of germinal center B cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol 1991; 21:1107-14.
Matsumo T, Miike T, Yamaguchi K, Murakami M, Kawabe T, Yodoi J. Serum levels of soluble IL-2 receptor, IL-4 and IgE-binding factors in childhood allergic diseases. Clin Exp Immunol 1991; 85:288-92.
Sarfati M, Bron D, Lagneaux L, Fonteyn C, Frost H, Delespesse G. Elevation of IgE-binding factors in serum patients with B-cell-derived chronic lymphocytic leukemia. Blood 1988; 71:94-98.
Beguin Y, Lampertz S, De Groote D, Igot D, Malaise M, Fillet G. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia. Leukemia 1993; 7:2019-25.
Bansal A, Roberts T, Hay EM, Kay R, Pumphrey RSH, Wilson PB. Soluble CD23 levels are elevated in the serum of patients with primary Sjögren's syndrome and systemic lupus erythematosus. Clin Exp Immunol 1992; 89:452-5.
Bansal AS, Ollier W, Marsh MN, Pumphrey RSH, Wilson PB. Variations in serum sCD23 in conditions with either enhanced humoral or cell-mediated immunity. Immunology 1993; 79:285-9.
Takei M, Azuhata T, Yoshimatu T, Shigihara S, Hashimoto S, Horie T, Horikoshi A, Sawada S. Increased soluble CD23 molecules in serum/saliva and correlation with the stage of sialoectasis in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 1995; 13:711-5.
Sato S, Fujimoto M, Kikuchi K, Ihn H, Tamaki K, Takehara K. Elevated soluble CD23 levels in the sera from patients with localized scleroderma. Arch Dermatol Res 1996; 288:74-78.
Roblot P, Morel F, Lelievre E, Biais-Sauvetre MH, De Groote D, Preud'homme JL, Lecron JC. Serum soluble CD23 levels in giant cell arteritis. Immunol Letters 1996; 53:41-44.
Kutukculer N, Caglayan S. Plasma and synovial fluid soluble CD23 concentrations in children with juvenile chronic arthritis. Autoimmunity 1998; 27:155-8.
Massa M, Pignatti P, Oliveri M, De Amici M, De Benedetti F, Martini A. Serum soluble CD23 levels and CD23 expression on peripheral blood mononuclear cells in juvenile chronic arthritis. Clin Exp Rheumatol 1998; 16:611-6.
Chomarat P, Briolay J, Banchereau J, Miossec P. Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4. Arthritis Rheum 1993; 36:234-42.
Izikawa K, Yanagihara Y, Kajiwara K, Koshio T, Shida T, Yamada A. Possible role of CD5+ B cells expressing CD23 in mediating elevation of serum-soluble CD23 in patients with rheumatoid arthritis. Int Arch Allergy Immunol 1993; 101:416-24.
Rezonzew R, Newkirk MM. Impaired release of sCD23 by activated B-cells from RA patients. Clin Immunol Immunopathol 1994; 71:156-63.
Loza E, Tinturé T, Sanchez-Ibarrola A. CD5 and CD23 expression on B cells in peripheral blood and synovial fluid of rheumatoid arthritis: relationship with interleukin-4, soluble CD23 and tumor necrosis factor alpha levels. Rheumatol 1999; 38:325-8.
Fernandez-Gutierrez B, Hernandez-Garcia C, Banares AA, Jover JA. CD23 hyperexpression in rheumatoid arthritis: evidence for a B cell hyperresponsiveness to cognate and noncognate T-cell signals. Clin Immunol Immunopathol 1994; 72:321-7.
Bansal AS, MacGregor AJ, Pumphrey RSH, Silman AJ, Ollier WER, Wilson PN. Increased levels of sCD23 in rheumatoid arthritis are related to disease status. Clin Exp Rheumatol 1994; 12:281-5.
Hellen EA, Rowlands DC, Hansel TT, Kitas GD, Crocker J. Immunohistochemical demonstration of CD23 expression on lymphocytes in rheumatoid synovitis. J Clin Pathol 1991; 44:293-6.
Roussou E, Gordon J, Sykes C, Farr M, Luqmani R, Sheeran T, Bacon PA, Emery P. Soluble CD23 expression in patients with rheumatoid arthritis. Br J Rheumatol 1991; 30 (Suppl. 2):110(Abstr.).
Armant M, Ishihara H, Rubio M, Delespesse G, Sarfati M. Regulation of cytokine production by soluble CD23: costimulation of interferon γ secretion and triggering of tumor necrosis factor α release. J Exp Med 1994; 180:1005-11.
Lecoanet-Henchoz S, Gauchat JF, Aubry JP et al. CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD11b-CD18 and CD11c-CD18. Immunity 1995; 3:119-25.
Partsch G, Steiner G, Leeb BF, Dunky A, Bröll H, Smolen JS. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24:518-23.
Plater-Zyberk C, Bonnefoy JY. Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo. Nature Med 1995; 1:781-5.
Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
Steiner G, Studnicka-Benke A, Witzmann G, Höfler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol 1995; 22:406-12.
Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977; 18:481-9.
Bonnefoy JY, Plater-Zyberk C, Lecoanet-Henchoz S, Gauchat JF, Aubry JP, Graber P. A new role for CD23 in inflammation. Immunol Today 1996; 17:418-20.
Kleinau S, Martinsson P, Gustavsson S, Heyman B. Importance of CD23 for collagen-induced arthritis: delayed onset and reduced severity in CD23-deficient mice. J Immunol 1999; 162:4266-70.
Walker DJ, Pound JD, Griffiths ID, Powell RJ. Rheumatoid factor tests in the diagnosis and prediction of rheumatoid arthritis. Ann Rheum Dis 1986; 45:684-90.
McIntyre KW, Shuster DJ, Gillooly KM et al. Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice. Eur J Immunol 1996; 26:2933-8.
Germann T, Szeliga J, Hess H, Storkel S, Podalski FJ, Gately MK, Schmitt E, Rude E. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci USA 1995; 92:4823-7.
Fischer A, König W. Regulation of CD23 expression, soluble CD23 release and immunoglobulin synthesis of peripheral blood lymphocytes by glucocorticoids. Immunology 1990; 71:473-9.
Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Morel Fourrier B, Galanaud P, Emilie D. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994; 37:1647-55.
Cush JJ, Splawski JB, Thomas R, McFarlin JE, Schulze-Koops H, Davis LS, Fujita K, Lipsky PE. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:96-104.
Bucht A, Larsson P, Weisbrot L, Thorne C, Pisa P, Smedegard G, Keystone EC, Gronberg A. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol 1996; 103:357-67.
Isomäki P, Luukkainen R, Saario R, Toivanen P, Punnonen J. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996; 39:386-95.
Howard M, O'Garra A, Ishida H, de Waal Malefyt R, de Vries J. Biological properties of interleukin 10. J Clin Immunol 1992; 12:239-47.
Rousset F, Garcia E, Defrance T et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89:1890-3.
Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24:629-39.
Maini RN, Paulus H, Breedveld PC et al. rHuIL-10 in subjects with active rheumatoid arthritis (RA): a phase I and cytokine response study. Arthritis Rheum 1997; 40 (Suppl.):S224(Abstr.).
Morinobu A, Kumagai S, Yanagida H, Ota H, Ishida H, Matsui M, Yodoi J, Nakao K. IL-10 suppresses cell surface CD23/Fc epsilon RII expression, not by enhancing soluble CD23 release, but by reducing CD23 mRNA expression in human monocytes. J Clin Immunol 1996; 16:326-33.
Becker H, Potyka P, Weber C, Federlin K. Detection of circulating FcεR2/CD23+ monocytes in patients with rheumatic diseases. Clin Exp Immunol 1991; 85:61-65.
Luukkainen R, Alanaatu A, Kaarela K, Huhtala H. Predictive value of synovial fluid analysis in rheumatoid arthritis. A 7.5-year follow-up study. Eur J Med 1993; 2:284-6.
Aman S, Risteli J, Luukkainen R, Risteli L, Kauppi M, Nieminen P, Hakal M. The value of synovial fluid analysis in the assessment of knee joint destruction in arthritis in a three year follow up study. Ann Rheum Dis 1999; 58:559-62.
Neidel J, Schulze M, Lindschau J. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor α in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 1995; 44:217-21.
